{"id":"ly2216684","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug targets the 5-HT7 receptor, a G-protein coupled receptor involved in circadian rhythm regulation and mood control. By blocking this receptor, LY2216684 may help normalize sleep-wake cycles and improve mood symptoms. This mechanism is distinct from traditional SSRIs and may offer benefits in conditions where circadian dysregulation contributes to pathology.","oneSentence":"LY2216684 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:53.291Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Circadian rhythm sleep disorders"}]},"trialDetails":[{"nctId":"NCT00965419","phase":"PHASE2, PHASE3","title":"A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2009-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":267},{"nctId":"NCT01263106","phase":"PHASE1","title":"A Study of LY2216684 and Theophylline in Healthy Subjects","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":21},{"nctId":"NCT01380691","phase":"PHASE1","title":"A Study of LY2216684 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-06","conditions":"Major Depressive Disorder","enrollment":28},{"nctId":"NCT01275144","phase":"PHASE1","title":"A Study of the Effect of LY2216684 on Lorazepam","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":28},{"nctId":"NCT01243957","phase":"PHASE1","title":"A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":"Major Depressive Disorder","enrollment":20},{"nctId":"NCT01263197","phase":"PHASE1","title":"A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":48},{"nctId":"NCT01263119","phase":"PHASE1","title":"A Study of LY2216684 and Warfarin in Healthy Subjects","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":18},{"nctId":"NCT01250873","phase":"PHASE1","title":"A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Major Depressive Disorder","enrollment":20},{"nctId":"NCT01389752","phase":"PHASE1","title":"A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-07","conditions":"Depressive Disorder, Major","enrollment":22},{"nctId":"NCT01389765","phase":"PHASE1","title":"A Study to Evaluate the Effect of Food on LY2216684","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-07","conditions":"Depressive Disorder, Major","enrollment":24},{"nctId":"NCT01460381","phase":"PHASE1","title":"A Study to Evaluate the Effect of Genotype on LY2216684","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-10","conditions":"Depressive Disorder, Major","enrollment":18},{"nctId":"NCT01370499","phase":"PHASE3","title":"A Study of LY2216684 in Participants With Major Depression Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-08","conditions":"Major Depressive Disorder","enrollment":288},{"nctId":"NCT01263223","phase":"PHASE1","title":"A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":24},{"nctId":"NCT01373931","phase":"PHASE1","title":"A Study of LY2216684 in Healthy Females","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-06","conditions":"Depressive Disorder, Major","enrollment":20},{"nctId":"NCT01263093","phase":"PHASE1","title":"A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":47},{"nctId":"NCT01241435","phase":"PHASE1","title":"A Study of LY2216684 in Participants With Impaired Hepatic Function","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":"Depressive Disorder, Major","enrollment":36},{"nctId":"NCT01266590","phase":"PHASE1","title":"A Study of LY2216684 and Digoxin in Healthy Subjects","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":30},{"nctId":"NCT01460407","phase":"PHASE1","title":"A Study to Evaluate the Effect of Clarithromycin on LY2216684","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-10","conditions":"Depressive Disorder, Major","enrollment":14},{"nctId":"NCT00420004","phase":"PHASE2","title":"A Study for Participants With Major Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-12","conditions":"Major Depressive Disorder","enrollment":469},{"nctId":"NCT01185340","phase":"PHASE3","title":"A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-03","conditions":"Major Depressive Disorder","enrollment":1056},{"nctId":"NCT00840034","phase":"PHASE2","title":"A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-02","conditions":"Depressive Disorder, Major","enrollment":227},{"nctId":"NCT01187407","phase":"PHASE3","title":"A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-03","conditions":"Major Depressive Disorder (MDD)","enrollment":1480},{"nctId":"NCT01299272","phase":"PHASE3","title":"A Study in Prevention of Re-emergence of Depression Symptoms","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-05","conditions":"Major Depressive Disorder","enrollment":1249},{"nctId":"NCT01173601","phase":"PHASE3","title":"A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Major Depressive Disorder","enrollment":1416},{"nctId":"NCT01155661","phase":"PHASE3","title":"A Safety Study in Participants With Major Depressive Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":"Depressive Disorder, Major","enrollment":608},{"nctId":"NCT00795821","phase":"PHASE2, PHASE3","title":"A Study in Adult Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-12","conditions":"Depressive Disorder, Major","enrollment":495},{"nctId":"NCT00922636","phase":"PHASE2, PHASE3","title":"A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":340}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Edivoxetine"],"phase":"phase_3","status":"active","brandName":"LY2216684","genericName":"LY2216684","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY2216684 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders. Used for Major depressive disorder, Circadian rhythm sleep disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}